Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA HEALTH GROUP INC.

中國醫療集團有限公司

(Carrying on business in Hong Kong as "萬全醫療集團")
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 08225)

(1) DELAY IN PUBLICATION OF FIRST QUARTERLY RESULTS AND DESPATCH OF THE REPORT FOR THE THREE MONTHS ENDED 31 MARCH 2019

AND

(2) CONTINUED SUSPENSION OF TRADING

This announcement is made by China Health Group Inc. (the "Company") pursuant to Rule 18.66, Rule 18.79 of the Rule Governing the Listing of Securities on GEM (the "Listing Rules") of The Stock Exchange of Hong Kong Limited (the "Stock Exchange").

DELAY IN PUBLICATION OF FIRST QUARTERLY RESULTS AND DESPATCH OF THE REPORT FOR THE THREE MONTHS ENDED 31 MARCH 2019

Pursuant to Rules 18.66 and 18.79 of the GEM Listing Rules, the Company must publish its quarterly results announcement (the "2019 First Quarterly Results Announcement") and despatch its quarterly report (the "2019 First Quarterly Report"), in respect of the first three months ended 31 March 2019, not later than 45 days after the end of the first quarter, i.e. 15 May 2019. As the publication of the Results Announcement of 2018 Annual Results is still pending, the Company is unable to make the 2019 First Quarterly Results Announcement and despatch the 2019 First Quarterly Report to its shareholders within the prescribed time in accordance with the GEM Listing Rules.

The Company will publish further announcements in due course to inform its shareholders in relation to the release and the despatch of its annual report in respect of the year ended 31

December 2018 and the 2019 First Quarterly Report.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares on the Stock Exchange has been suspended with effect from 9:00 a.m. on 1 April 2019 and will continue to be suspended until further notice.

Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board China Health Group Inc. William Xia GUO

Hong Kong, 15 May 2019

As at the date hereof, the Board comprises two executive directors, being Mr. William Xia GUO and Dr. Maria Xue Mei SONG; one non-executive director, being Mr. Michael SU; and four independent non-executive directors, being Mr. Rui QIU, Mr. Mark Gavin LOTTER, Dr. Bin Hui NI and Mr. Ling ZHEN.

This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website with the domain name of www.hkgem.com on the "Latest Company Announcements" page for at least 7days from the date of its posting and on the Company's website at www.chgi.net.